Literature DB >> 33619313

Three-dimensional structure of human cyclooxygenase (hCOX)-1.

Morena Miciaccia1, Benny Danilo Belviso2, Mariaclara Iaselli1, Gino Cingolani3, Savina Ferorelli1, Marianna Cappellari4, Paola Loguercio Polosa4, Maria Grazia Perrone1, Rocco Caliandro5, Antonio Scilimati6.   

Abstract

The beneficial effects of Cyclooxygenases (COX) inhibitors on human health have been known for thousands of years. Nevertheless, COXs, particularly COX-1, have been linked to a plethora of human diseases such as cancer, heart failure, neurological and neurodegenerative diseases only recently. COXs catalyze the first step in the biosynthesis of prostaglandins (PGs) and are among the most important mediators of inflammation. All published structural work on COX-1 deals with the ovine isoenzyme, which is easier to produce in milligram-quantities than the human enzyme and crystallizes readily. Here, we report the long-sought structure of the human cyclooxygenase-1 (hCOX-1) that we refined to an R/Rfree of 20.82/26.37, at 3.36 Å resolution. hCOX-1 structure provides a detailed picture of the enzyme active site and the residues crucial for inhibitor/substrate binding and catalytic activity. We compared hCOX-1 crystal structure with the ovine COX-1 and human COX-2 structures by using metrics based on Cartesian coordinates, backbone dihedral angles, and solvent accessibility coupled with multivariate methods. Differences and similarities among structures are discussed, with emphasis on the motifs responsible for the diversification of the various enzymes (primary structure, stability, catalytic activity, and specificity). The structure of hCOX-1 represents an essential step towards the development of new and more selective COX-1 inhibitors of enhanced therapeutic potential.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33619313      PMCID: PMC7900114          DOI: 10.1038/s41598-021-83438-z

Source DB:  PubMed          Journal:  Sci Rep        ISSN: 2045-2322            Impact factor:   4.379


  48 in total

1.  Novel selective COX-1 inhibitors suppress neuroinflammatory mediators in LPS-stimulated N13 microglial cells.

Authors:  Rosa Calvello; Maria Antonietta Panaro; Maria Luigia Carbone; Antonia Cianciulli; Maria Grazia Perrone; Paola Vitale; Paola Malerba; Antonio Scilimati
Journal:  Pharmacol Res       Date:  2011-10-01       Impact factor: 7.658

2.  VMD: visual molecular dynamics.

Authors:  W Humphrey; A Dalke; K Schulten
Journal:  J Mol Graph       Date:  1996-02

3.  The X-ray crystal structure of the membrane protein prostaglandin H2 synthase-1.

Authors:  D Picot; P J Loll; R M Garavito
Journal:  Nature       Date:  1994-01-20       Impact factor: 49.962

4.  Comparison of structural stabilities of prostaglandin H synthase-1 and -2.

Authors:  G Xiao; W Chen; R J Kulmacz
Journal:  J Biol Chem       Date:  1998-03-20       Impact factor: 5.157

5.  Synthesis and biological evaluation of new clofibrate analogues as potential PPARalpha agonists.

Authors:  Maria Grazia Perrone; Ernesto Santandrea; Natalina Dell'Uomo; Fabio Giannessi; Ferdinando Maria Milazzo; Anna Floriana Sciarroni; Antonio Scilimati; Vincenzo Tortorella
Journal:  Eur J Med Chem       Date:  2005-02       Impact factor: 6.514

6.  Comparison of cyclooxygenase-1 crystal structures: cross-talk between monomers comprising cyclooxygenase-1 homodimers.

Authors:  Ranjinder S Sidhu; Jullia Y Lee; Chong Yuan; William L Smith
Journal:  Biochemistry       Date:  2010-08-24       Impact factor: 3.162

7.  Constrained analogues of tocainide as potent skeletal muscle sodium channel blockers towards the development of antimyotonic agents.

Authors:  Alessia Catalano; Alessia Carocci; Filomena Corbo; Carlo Franchini; Marilena Muraglia; Antonio Scilimati; Michela De Bellis; Annamaria De Luca; Diana Conte Camerino; Maria Stefania Sinicropi; Vincenzo Tortorella
Journal:  Eur J Med Chem       Date:  2008-01-31       Impact factor: 6.514

8.  Selective COX-1 inhibition as a target of theranostic novel diarylisoxazoles.

Authors:  Paola Vitale; Maria Grazia Perrone; Paola Malerba; Antonio Lavecchia; Antonio Scilimati
Journal:  Eur J Med Chem       Date:  2014-01-02       Impact factor: 6.514

9.  Translational impact of novel widely pharmacological characterized mofezolac-derived COX-1 inhibitors combined with bortezomib on human multiple myeloma cell lines viability.

Authors:  Maria Laura Pati; Paola Vitale; Savina Ferorelli; Mariaclara Iaselli; Morena Miciaccia; Angelina Boccarelli; Giuseppe Davide Di Mauro; Cosimo G Fortuna; Thaisa Francielle Souza Domingos; Luiz Cláudio Rodrigues Pereira da Silva; Marcelo de Pádula; Lucio Mendes Cabral; Plínio Cunha Sathler; Angelo Vacca; Antonio Scilimati; Maria Grazia Perrone
Journal:  Eur J Med Chem       Date:  2018-12-15       Impact factor: 6.514

10.  Overview of the CCP4 suite and current developments.

Authors:  Martyn D Winn; Charles C Ballard; Kevin D Cowtan; Eleanor J Dodson; Paul Emsley; Phil R Evans; Ronan M Keegan; Eugene B Krissinel; Andrew G W Leslie; Airlie McCoy; Stuart J McNicholas; Garib N Murshudov; Navraj S Pannu; Elizabeth A Potterton; Harold R Powell; Randy J Read; Alexei Vagin; Keith S Wilson
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2011-03-18
View more
  3 in total

1.  Biological Evaluation and Molecular Docking Studies of Novel 1,3,4-Oxadiazole Derivatives of 4,6-Dimethyl-2-sulfanylpyridine-3-carboxamide.

Authors:  Piotr Świątek; Teresa Glomb; Agnieszka Dobosz; Tomasz Gębarowski; Kamil Wojtkowiak; Aneta Jezierska; Jarosław J Panek; Małgorzata Świątek; Małgorzata Strzelecka
Journal:  Int J Mol Sci       Date:  2022-01-04       Impact factor: 5.923

2.  Fluorochrome Selection for Imaging Intraoperative Ovarian Cancer Probes.

Authors:  Maria Grazia Perrone; Paola Vitale; Morena Miciaccia; Savina Ferorelli; Antonella Centonze; Roberta Solidoro; Cristina Munzone; Carmela Bonaccorso; Cosimo Gianluca Fortuna; Katrin Kleinmanns; Line Bjørge; Antonio Scilimati
Journal:  Pharmaceuticals (Basel)       Date:  2022-05-26

Review 3.  Structural basis for endoperoxide-forming oxygenases.

Authors:  Takahiro Mori; Ikuro Abe
Journal:  Beilstein J Org Chem       Date:  2022-06-21       Impact factor: 2.544

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.